Form 4: Kiniksa Pharmaceuticals Executive Michael Megna Reports Share Transactions

Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Summary

• Michael Megna, the Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, filed a Form 4 detailing changes in beneficial ownership.
• On April 7, 2025, Megna acquired 3,933 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs).
• Also on April 7, 2025, Megna disposed of 1,666 Class A Ordinary Shares at a price of $20.28.
• Following these transactions, Megna directly owns 32,546 Class A Ordinary Shares and 3,932 Restricted Share Units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The information disclosed is consistent with regulatory requirements for insider trading reporting.
• Similar filings can be observed for executives at comparable pharmaceutical companies like Amgen, Regeneron, and Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Kiniksa Pharmaceuticals, KNSA, Michael Megna, Restricted Share Units, Class A Ordinary Shares, Share Transactions